English Session

Symposium

S4

Recent advances in inflammatory arthritis, osteoporosis, locomotive syndrome and frailty

Monday, April 24 9:30-12:00 Room 13 International Conference Room 501, Fukuoka International Congress Center

Chairs:

Thomas Huizinga

Leiden University Medical Center, The Netherlands

Atsushi Kawakami

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan

S4-1

Recent understanding of Pre-RA and Early RA

Thomas Huizinga

Leiden University Medical Center, The Netherlands

S4-2

Safety profile of bDMARDs and tsDMARDs for inflammatory arthritis (tentative)

Kevin Winthrop

Oregon Health & Science University, USA

S4-3

Management of psoriatic arthritis with pharmacological therapies (tentative)

Daniel Aletaha

Medical University of Vienna, Austria

S4-4

Molecular understanding of phamacological treatment of osteoporosis

Sakae Tanaka

Department of Orthopaedic Surgery, The University of Tokyo, Tokyo, Japan

S4-5

Real world evidence of locomotive syndrome and frailty:The ROAD study

Noriko Yoshimura

Department of Preventive Medicine for Locomotive Organ Disorders, 22nd Century Medical and Research Center, The University of Tokyo, Japan

S10

The latest frontier in treatment of SLE

Tuesday, April 25 14:40-17:10 Room 1 Fukuoka Sunpalace Hall

Chairs:

Yoshiya Tanaka

The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

Isao Matsumoto

Department of Rheumatology, Institute of Medicine, University of Tsukuba, Japan

S10-1

Targeting B Cells in Systemic Lupus Erythematosus

Richard A. Furie

Northwell Health and Zucker School of Medicine, Division of Rheumatology, USA

S10-2

New Frontiers in SLE Therapy: Omics-informed Targeted Therapy to Restore the Aberrant Transcriptional Landscape in Systemic Lupus Erythematosus (SLE)

Dimitrios T. Boumpas

National and Kapodistrian University of Athens, Greece

S10-3

IFN targeting in SLE

Eric F. Morand

Monash University, Australia

S10-4

Targeting the JAK in the treatment of SLE

Shingo Nakayamada

The First Department of Internal Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Japan

S10-5

CAR-T

Georg Schett

Friedrich-Alexander-University Erlangen-Nürnberg, Germany

S13

TREG Analysis of EULAR 2022, ACR2022 Conference

Wednesday, April 26 9:30-12:00 Room 1 Fukuoka Sunpalace Hall

Chairs:

Yoshiya Tanaka

The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

Kazuhiko Yamamoto

RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

S13-1

Rheumatoid Arthritis: Key recent developments

Arthur Kavanaugh

University of California San Diego, USA

S13-2

Spondyloarthritis (tentative)

Philip J. Mease

University of Washington School of Medicine, Seattle, WA, USA

S13-3

EULAR/ACR Convergence 2022 SLE/Early-phase new molecules

Roy Fleischmann

University of Texas Southwestern Medical Center, USA

S13-4

Autoimmune Inflammatory Rheumatic Diseases: Presentations from the American College of Rheumatology Annual Meeting

Allan Gibofsky

Weill Cornell Medicine and Attending Rheumatologist Hospital for Special Surgery, New York, NY, USA

S16

Basic & Translational research

Wednesday, April 26 9:30-12:00 Room 13 International Conference Room 501, Fukuoka International Congress Center

Chairs:

Sachiko Miyake

Department of Immunology, Juntendo University Graduate School of Medicine, Japan

Georg Schett

Friedrich Alexander University, Germany

S16-1

Synovial fibroblast in joint diseases

Georg Schett

Friedrich Alexander University, Germany

S16-2

Synovial tissue macrophages in rheumatoid arthritis

Iain B. Mcinnes

University of Glasgow, UK

S16-3

The mechanism of enhanced production of type I interferon in SLE（Tentitive）

Virginia Pascual

Drukier Institute for Children’s Health, Weill Cornell Medicine, New York, NY, USA

S16-4

Immunophenotypic analysis of systemic lupus erythematosus

Shingo Nakayamada

The First Department of Internal Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Japan

S16-5

Immunological pathogenesis of systemic lupus erythematosus revealed by the functional genome analysis

Keishi Fujio

Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan

S20

Recent advances and challenges in the management of systemic autoimmune inflammatory diseases

Wednesday, April 26 13:35-16:05 Room 13 International Conference Room 501, Fukuoka International Congress Center

Chairs:

Eric F. Morand

Monash University, Australia

Hideto Kameda

Division of Rheumatology, Department of Internal Medicine, Toho University, Japan

S20-1

Evaluation of the disease activity and therapeutic management of Takayasu arteritis

Yoshikazu Nakaoka

Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Japan

S20-2

Recent advances and challenges in the management of SLE

Eric F. Morand

Monash University, Australia

S20-3

Recent advances and challenges in the management of systemic sclerosis (tentative)

Vincent Cottin

Louis Pradel University Hospital and Claude Bernard University, France

S20-4

Recent advances and challenges in the management of dermatomyositis/polymyositis

Rohit Aggarwal

Division of Rheumatology, Department of Medicine, University of Pittsburgh, USA

S20-5

Recent advances and challenges in the concept and management of overlap syndrome including MCTD

Hideto Kameda

Division of Rheumatology, Department of Internal Medicine, Toho University, Japan

Special Symposium

SS2 (APLAR Session)

Science of Rheumatology - an Asia Pacific Accent

Monday, April 24 15:10-17:20 Room 13 International Conference Room 501, Fukuoka International Congress Center

Chairs:

Hideto Kameda

Division of Rheumatology, Department of Internal Medicine, Toho University, Japan

Masataka Kuwana

Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan

SS2-1

Applying evidence to the practice of rheumatology in the Asia Pacific region: challenges and opportunities

Samuel L. Whittle

The Queen Elizabeth Hospital, Adelaide, Australia

SS2-2

Genetic background in SLE - East Asian variants

Sang-Cheol Bae

Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

SS2-3

A molecular approach to management of polygenic auto-inflammatory diseases

Ibrahim Almaghlouth

King Saud University, Riyadh, Saudi Arabia

SS2-4

Takayasu arteritis (TAK) is not a young onset GCA - nor the vice versa

Debashish Danda

Department of Clinical Immunology and Rheumatology, Christian Medical College and Hospital, Vellore, India

SS2-5

The latest APLAR guideline on management of Gout (tentative)

Sami Salman

Baghdad Medical College, Baghdad,Iraq

SS3 (ACR Session)

Targeted Therapies in RA and Scleroderma

Tuesday, April 25 8:55-10:55 Room 13 International Conference Room 501, Fukuoka International Congress Center

Chairs:

Kazuhiko Yamamoto

RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

Kunihiro Yamaoka

Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Japan

SS3-1

Targeted therapies in rheumatoid arthritis: reality check

Elena Myasoedova

Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, USA

SS3-2

Advances in the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease

Elizabeth R. Volkmann

University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA

SS4 (EULAR Session)

When Imaging meets clinical evaluation in RMDs: artifacts or reality?

Tuesday, April 25 15:00-17:00 Room 13 International Conference Room 501, Fukuoka International Congress Center

Chairs:

Tsutomu Takeuchi

Saitama Medical University, Keio University, Japan

Atsushi Kawakami

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan

SS4-1

Imaging in connective tissue diseases

Annamaria Iagnocco

University of Turin, Italy

SS4-2

When Imaging meets clinical evaluation in RMDs: artifacts or reality?

Xenofon Baraliakos

Ruhr-University Bochum, Bochum, Germany

SS4-3

Remission criteria: do current definitions reflect a real remission? (tentative)

Daniel Aletaha

Medical University of Vienna, Austria

SS4-4

Optimal treatment strategies in RMDs: is clinical guidance the best option?

Iain B. Mcinnes

University of Glasgow, UK

Educational Lecture

EL12

Outcome Measures in Systemic Sclerosis

Tuesday, April 25 10:00-11:00 Room 4 International Conference Room 203, Fukuoka International Congress Center

Chair:

Masataka Kuwana

Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan

EL12

Outcome Measures in Systemic Sclerosis

Lecturer:

Dinesh Khanna

University of Michigan, Michigan, USA

Morning Seminar

MS7

Interstitial lung disease associated with connective tissue disease

Wednesday, April 26 7:30-8:30 Room 2 Fukuoka Sunpalace A＋B

Chair:

Yoshiya Tanaka

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan

Speaker:

Vincent Cottin

Louis Pradel University Hospital and Claude Bernard University, France

Sponsor:: Nippon Boehringer Ingelheim Co., Ltd.

MS8

The Role of IL-6 Receptor Inhibitors in Rheumatoid Arthritis

Wednesday, April 26 7:30-8:30 Room 4 International Conference Room 203, Fukuoka International Congress Center

Chair:

Takahiko Horiuchi

Kyushu University Beppu Hospital, Japan

Speaker:

Allan Gibofsky

Weill Cornell Medical College and Hospital for Special Surgery, USA

Sponsor:: ASAHI KASEI PHARMA CORPORATION

Luncheon Seminar

LS1

The Impact of Filgotinib for Achieving Clinical and Structural Remission

Monday, April 24 13:00-14:00 Room 1 Fukuoka Sunpalace Hall

Chair:

Tshutomu Takeuchi

Vice President of Saitama Medical University Emeritus Professor, Keio University

Speaker:

Aletaha Daniel

Medical University Vienna Division of Rheumatology Department of Internal Medicine 3

Sponsor:: Gilead Sciences K.K. / Eisai Co., Ltd.

LS5

What about Hot Topics in PsA - focus on Guselkumab

Monday, April 24 13:00-14:00 Room 5 International Conference Room 204, Fukuoka International Congress Center

Chair:

Keishi Fujio

Department of Allergy and Rheumatology, Graduation School of Medicine, the Tokyo University of Tokyo

Speaker:

Peter Nash

The School of Medicine at Griffith University, Queensland, Australia Rheumatology Research Unit

Sponsor:: Janssen Pharmaceutical K.K.

LS6

The Role of IL6 in Optimizing Treatment in Patient with Rheumatoid Arthritis

Monday, April 24 13:00-14:00 Room 6 Fukuoka International Congress Center Main Hall

Chair:

Hideto Kameda

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

Speaker:

Thomas Huizinga

Leiden University Medical Cente Department of Rheumatology

Sponsor:: ASAHI KASEI PHARMA CORPORATION

LS15

Efficacy and safety of filgotinib in rheumatoid arthritis

Tuesday, April 25 12:40-13:40 Room 1 Fukuoka Sunpalace Hall

Chair:

Yoshiya Tanaka

Professor, Division of Rheumatology, Department of Internal Medicine 3, Medical University Vienna

LS15-1

The Evolution of RA Therapy From Biologics to the JAK Inhibitor Filgotinib: Aiming for Clinical and Structural Remission

Speaker：

Aletaha Daniel

Medical University Vienna Division of Rheumatology Department of Internal Medicine 3

Discussant:

Kei Ikeda

Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan

Yohei Kirino

Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Japan

Satoshi Kubo

Associate Professor, Department of Molecular Targeted Therapies (DMTT), School of Medicine University of Occupational and Environmental Health Japan, Fukuoka, Japan

Sponsor:: Gilead Sciences K.K. / Eisai Co., Ltd.

LS17

Tofacitinib, a clinically effective JAK inhibitor in the treatment of Rheumatoid Arthritis and safety lessons learned from Oral Surveillance

Tuesday, April 25 12:40-13:40 Room 3 International Conference Room 201+202, Fukuoka International Congress Center

Chair:

Kunihiro Yamaoka

Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine

Speaker:

Fleischmann Roy

University of Texas Southwestern Medical Center, Dallas, TX, USA

Sponsor:: Pfizer Japan Inc.

LS30

Implementing Treat to Target in Clinical Practice for Systemic Lupus Erythematosus

Wednesday, April 26 12:20-13:20 Room 3 International Conference Room 201+202, Fukuoka International Congress Center

Chair:

Tatsuya Atsumi

Faculty of Medicine, Hokkaido University, Hokkaido, Japan Department of Rheumatology, Endocrinology and Nephrology

Speaker:

Dimitrios T. Boumpas

National and Kapodistrian University of Athens, Greece Rheumatology and Clinical Immunology

Sponsor:: AstraZeneca K.K.

LS41

An update on systemic sclerosis

Wednesday, April 26 12:20-13:20 Room 17 国際センター研修室1

Chair:

Masataka Kuwana

Department of Allergy and Rheumatology, Nippon Medical School, Japan

Speaker:

Khanna Dinesh

University of Michigan, Ann Arbor, USA

Sponsor:: Nippon Boehringer Ingelheim Co., Ltd.

Evening Seminar

ES1

Latest Findings in Rheumatoid Arthritis Treatment

Monday, April 24 17:40-19:10 Room 1 Fukuoka Sunpalace Hall

Chair:

Hiroshi Takayanagi

Department of Immunology, Graduate School of Medicine and Faculty of Medicine The University of Tokyo

ES1-1

Role of Abatacept in the era of molecular targeted therapies.

Speaker:

Motomu Hashimoto

Osaka Metropolitan University Graduate School of Medicine Department of Clinical Immunology

ES1-2

Further development beyond RA and beyond biologicals

Speaker:

Tom W Huizinga

Leiden University Medical School, The Netherlands

Sponsor:: Bristol-Myers Squibb K.K. / ONO PHARMACEUTICAL CO., LTD.

ES4

Future perspectives: JAK inhibitors in the treatment of Rheumatoid Arthritis

Monday, April 24 17:40-19:10 Room 4 International Conference Room 203, Fukuoka International Congress Center

Chair:

Mitsumasa Kishimoto

Kyorin University School of Medicine, Department of Nephrology and Rheumatology

Speaker:

Kavanaugh Arthur

University of California, San Diego, School of Medicine, CA, USA Rheumatology, Allergy, Immunology Division

Sponsor:: Gilead Sciences K.K. / Eisai Co., Ltd.

ES6

Pursuit implementing Rheumatoid Arthritis Treatment for the Next Decade（Go above and beyond）

Monday, April 24 17:30-19:30 Room 6 Fukuoka International Congress Center Mail Hall

Discussant:

Sakae Tanaka

Department of Orthopaedic Surgery Fuculty of Medicine, Tokyo University

Moderator:

Tshutomu Takeuchi

Saitama Medical University / Keio University

Discussants:

Smolen Josef

Division of Rheumatology, Department of MedicineIII, Medical University of Vienna, Austria

Gard R. Burmster

Charité-University Medicine Berlin, Germany

Moderators:

Ryoji Noritake

Health and Global Policy Institute

Discussants:

Satoshi Kubo

Department of Molecular Targeted Therapies, School of Medicine, University of Occupational and Environmental Health, Japan

Yuko Kaneko

Division of Rheumatology Department of Internal Medicine, Keio University School of Medicine

Sonosuke Yukawa

Yukawa Rheumatology Clinic

ES6

Pursuit implementing Rheumatoid Arthritis Treatment for the Next Decade (Go above and beyond)

Discussants:

Yoshiya Tanaka

University of Occupational and Environmental Health, Japan The first department of internal medicine, School of Medicine

Kiyoshi Kurokawa

Health and Global Policy Institute

Sponsor:: Eli Lilly Japan K.K./Health and Global Policy Institute

ES10

A practical management of JAK inhibitors in the management of RA ～How JAK inhibitors help patients to reach treatment goals ～

Monday, April 24 17:30-19:20 Room 13 International Conference Room 501, Fukuoka International Congress Center

Chairs:

Kunihiro Yamaoka

Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine

Masayoshi Harigai

Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Japan

ES10-1

What we learned from ORAL Surveillance and how JAK inhibitors can help patients to reach treatment goals

Speaker:

Gerd R. Burmester

Charité University Medicine, Berlin, Germany Department of Rheumatology and Clinical Immunology

ES10-2

An overview of the benefit/risk and safety profile of JAK inhibitors in 2023

Speaker:

Winthrop Kevin

Oregon Health and Sciences University, Portland, Oregon USA Infectious Diseases and Public Health

Sponsor:: AbbVie GK

ES11

Recent progress in Systemic lupus erythematosus

Tuesday, April 25 17:20-18:50 Room 1 Fukuoka Sunpalace Hall

Chair:

Koichiro Omura

Department of Collagen Disease and Rheumatology, Kobe Municipal Medical Center Central Municipal Hospital

ES11-1

The role of anifrolumab in the treatment of systemic lupus erythematosus

Speaker:

Shingo Nakayamada

University of Occupational & Environmental Health, Japan, Kitakyushu, Japan The First Department of Internal Medicine

ES11-2

New therapeutic strategies in Systemic Lupus Erythematosus

Speaker:

Morand F. Eric

School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University

Sponsor:: AstraZeneca K.K.

ES13

Novel treatment strategies in rheumatoid arthritis

Tuesday, April 25 17:20-18:50 Room 3 International Conference Room 201+202, Fukuoka International Congress Center

Chair:

Kunihiro Yamaoka

Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine

ES13-1

Therapeutic targets for Rheumatoid Arthritis:Focus on IL-6 inhibitors

Speaker:

Tsutomu Takeuchi

Saitama Medical University/Keio University

ES13-2

The key role of Interleukin-6 on inflammation, bone loss and bone repair in rheumatoid arthritis

Speaker:

Schett Georg

Friedrich Alexander University Erlangen-Nurnberg, Germany Department of Internal Medicine 3 Rheumatology and Immunology

Sponsor:: CHUGAI PHARMACEUTICAL CO., LTD.

ES14

Innovative therapeutic alternatives for RA, PsA, AS and nr-axSpA

Tuesday, April 25 17:20-18:50 Room 4 International Conference Room 203, Fukuoka International Congress Center

Chair:

Mitsumasa Kishimoto

Nephrology and Rheumatology, Kyorin University School of Medicine, Associate professor

ES14-1

Emerging learnings in PsA: From clinical trials to clinical practice

Speaker:

Philip J. Mease

University of Washington School of Medicine

ES14-2

Challenges in the treatment of RA and the role of JAK inhibitors

Speaker:

Motomu Hashimoto

Osaka Metropolitan University Graduate School of Medicine Department of Clinical Immunology

Sponsor:: Eli Lilly Japan K.K.

ES21

Position of Belimumab in evidence-based SLE treatment

Tuesday, April 25 17:20-18:50 Room 13 International Conference Room 501, Fukuoka International Congress Center

Chair:

Hiroaki Niiro

Kyushu university Professor, Department of Medical Education, Faculty of Medical Sciences

ES21-1

The Position of Benlysta in the Evidence-Based Treatment of SLE/LN

Speaker:

Furie Richard

Northwell Healthand Zucker School of Medicine, Division of Rheumatology, USA

ES21-2

SLE patient suitable for belimumab inferred from real world data

Speaker:

Yusuke Miyazaki

First department of Internal Medicine, University of Occupational and Environmental Health, Japan

Sponsor:: GlaxoSmithKline. K.K.